The American Journal of Medicine
Volume 120, Issue 10, Supplement 2 , Pages S26-S34 , October 2007

Prevention and Management of Venous Thromboembolism in Pregnancy

  • Andra H. James, MD, MPH

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Andra H. James, MD, MPH, Division of Maternal and Fetal Medicine, Box 3967, Duke University Medical Center Durham, North Carolina 27710.

References 

  1. Dickson B. Venous thrombosis: on the history of Virchow’s Triad. University of Toronto Medical Journal. 2004;81:166–171
  2. Gordon M. Maternal physiology in pregnancy. In:  Gabbe S,  Niebyl J,  Simpson J editor. Normal and Problem Pregnancies. 4th ed.. New York: Churchill Livingstone; 2002;p. 63–92
  3. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol. 1997;104:191–197
  4. Whitty J, Dombrowski M. Respiratory diseases in pregnancy. In:  Gabbe S,  Niebyl J,  Simpson J editor. Normal and Problem Pregnancies. 4th ed.. New York: Churchill Livingstone; 2002;p. 1033–1064
  5. Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol. 2001;184:104–110
  6. Carr MH, Towers CV, Eastenson AR, Pircon RA, Iriye BK, Adashek JA. Prolonged bedrest during pregnancy: does the risk of deep vein thrombosis warrant the use of routine heparin prophylaxis?. J Matern Fetal Med. 1997;6:264–267
  7. Kovacevich GJ, Gaich SA, Lavin JP, Hopkins MP, Crane SS, Stewart J, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol. 2000;182:1089–1092
  8. Sikovanyecz J, Orvos H, Pal A, et al. Leiden mutation, bed rest and infection: simultaneous triggers for maternal deep-vein thrombosis and neonatal intracranial hemorrhage?. Fetal Diagn Ther. 2004;19:275–277
  9. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003;16:153–168
  10. Medcalf RL, Stasinopoulos SJ. The undecided serpin: the ins and outs of plasminogen activator inhibitor type 2. FEBS J. 2005;272:4858–4867
  11. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol. 2005;193:216–219
  12. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 1999;54:265–271
  13. Postpartum Hemorrhage: Postpartum Hemorrhage Initiative, Office of Health, Infectious Diseases and Nutrition, Bureau for Global Health, US Agency for International Development. http://www.pphprevention.org/pph.php. Accessed September 3, 2007.
  14. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance—United States, 1991–1999. MMWR Surveill Summ. 2003;52:1–8
  15. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697–706
  16. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194:1311–1315
  17. Bergqvist A, Bergqvist D, Lindhagen A, Matzsch T. Late symptoms after pregnancy-related deep vein thrombosis. Br J Obstet Gynaecol. 1990;97:338–341
  18. Ulander VM, Lehtola A, Kaaja R. Long-term outcome of deep venous thrombosis during pregnancy treated with unfractionated heparin or low molecular weight heparin. Thrombosis Research. 2003;111:239–242
  19. Rosfors S, Noren A, Hjertberg R, Persson L, Lillthors K, Torngren S. A 16-year haemodynamic follow-up of women with pregnancy-related medically treated iliofemoral deep venous thrombosis. Eur J Vasc Endovasc Surg. 2001;22:448–455
  20. Grandone E, Margaglione M, Colaizzo D, D’Andrea G, Cappucci G, Brancaccio V, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol. 1998;179:1324–1328
  21. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374–380
  22. McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210 G-- >A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG. 2000;107:565–569
  23. Dilley A, Austin H, El-Jamil M, et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol. 2000;183:1271–1277
  24. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 2002;87:791–795
  25. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–1508
  26. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171–196
  27. Pabinger I, Schneider B Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency: a cooperative, retrospective study. Arterioscler Thromb Vasc Biol. 1996;16:742–748
  28. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990;63:319–320
  29. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 1982;14:127–141
  30. Girling J, de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol. 1998;10:135–144
  31. Krnic-Barrie S, O’Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med. 1997;157:2101–2108
  32. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001;44:1466–1467
  33. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med. 1989;149:2233–2236
  34. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG. 2001;108:1134–1140
  35. Roberts D, Schwartz RS. Clotting and hemorrhage in the placenta—a delicate balance. N Engl J Med. 2002;347:57–59
  36. Brill-Edwards P, Ginsberg JS, Gent M, et al. Recurrence of Clot in This Pregnancy Study Group Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med. 2000;343:1439–1444
  37. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81:668–672
  38. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005;3:949–954
  39. De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 2006;135:386–391
  40. Pabinger I, Grafenhofer H, Kyrle PA, et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002;100:1060–1062
  41. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:627S–644S
  42. James AH, Brancazio LR, Ortel TL. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol. 2005;3:187–197
  43. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003;101:1333–1344
  44. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103:3695–3699
  45. American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy (ACOG Practice Bulletin No. 19). Washington, DC: ACOG; 2000;
  46. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol. 2002;99:333–341
  47. Moore KL. Organogenetic period: The fourth to eighth weeks. In: The Developing Human: Clinically Oriented Embryology. 6th ed.. Philadelphia: WB Saunders Company; 1998;p. 83–106
  48. Naimi TS, Lipscomb LE, Brewer RD, Gilbert BC. Binge drinking in the preconception period and the risk of unintended pregnancy: implications for women and their children. Pediatrics. 2003;111:1136–1141
  49. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med. 1986;315:1390–1393
  50. Sadler L, McCowan L, White H, Stewart A, Bracken M, North R. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG. 2000;107:245–253
  51. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160:191–196
  52. Nassar AH, Hobeika EM, Abd Essamad HM, Taher A, Khalil AM, Usta IM. Pregnancy outcome in women with prosthetic heart valves. Am J Obstet Gynecol. 2004;191:1009–1013
  53. Blickstein D, Blickstein I. The risk of fetal loss associated with warfarin anticoagulation. Int J Gynaecol Obstet. 2002;78:221–225
  54. Srivastava AK, Gupta AK, Singh AV, Husain T. Effect of oral anticoagulant during pregnancy with prosthetic heart valve. Asian Cardiovasc Thorac Ann. 2002;10:306–309
  55. Meschengieser SS, Fondevila CG, Santarelli MT, Lazzari MA. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart. 1999;82:23–26
  56. Chen WW, Chan CS, Lee PK, Wang RY, Wong VC. Pregnancy in patients with prosthetic heart valves: an experience with 45 pregnancies. Q J Med. 1982;51:358–365
  57. Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol. 2002;99:35–40
  58. Wesseling J, Van Driel D, Heymans HS, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost. 2001;85:609–613
  59. Harenberg J, Schneider D, Heilmann L, Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis. 1993;23:314–320
  60. Schneider D, Heilmann L, Harenberg J. Placental transfer of low-molecular weight heparin. [in German] Geburtshilfe Frauenheilkd. 1995;55:93–98
  61. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. 1994;170:1315–1320
  62. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol. 1994;170:862–869
  63. Casele H, Haney EI, James A, Rosene-Montella K, Carson M. Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol. 2006;195:1109–1113
  64. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168:1265–1270
  65. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol. 2001;185:148–152
  66. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. 2004;19:1211–1214
  67. Casele H, Haney E. Bruising in women undergoing thromboprophylaxis in pregnancy. [abstract] Am J Obstet Gynecol. 2006;193:S81
  68. Matziolis G, Perka C, Disch A, Zippel H. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int. 2003;73:370–379
  69. Lagrange F, Brun JL, Vergnes MC, et al. Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model. Clin Pharmacokinet. 2002;41:47–49
  70. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med. 2004;350:1914–1915
  71. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222–1226
  72. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood. 2006;108:1569–1570
  73. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:204S–233S
  74. Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod. 1997;12:2167–2173
  75. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335
  76. McCrae KR, Bussel JB, Mannucci PM, Remuzzi G, Cines DB. Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematology (Am Soc Hematol Educ Program). 2001;282:305
  77. Macchi L, Sarfati R, Guicheteau M, et al. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal’s disease. Clin Appl Thromb Hemost. 2000;6:187–189
  78. Woo YL, Allard S, Cohen H, Letsky E, de Swiet M. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia. BJOG. 2002;109:466–468
  79. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost. 2002;28:439–446
  80. Gill J, Kovacs MJ. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol. 1997;90:648–650
  81. Huhle G, Geberth M, Hoffmann U, Heene DL, Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest. 2000;49:67–69
  82. Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol. 2001;67:268–269
  83. Wijesiriwardana A, Lees DA, Lush C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis. 2006;17:147–149
  84. Vural KM, Ozatik MA, Uncu H, et al. Pregnancy after mechanical mitral valve replacement. J Heart Valve Dis. 2003;12:370–376
  85. Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants?. BMJ. 1977;1:1564–1565
  86. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–789
  87. Flessa HC, Kapstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am J Obstet Gynecol. 1965;93:570–573
  88. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis. 2000;30:243–248
  89. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost. 1992;68:652–656
  90. Taylor AA. Successful use of heparinoids in a pregnancy complicated by allergy to heparin. BJOG. 2001;108:1011–1012
  91. de Saint-Blanquat L, Simon L, Toubas MF, Hamza J. Treatment with danaparoid during pregnancy for a woman with a cutenous allergy to low-molecular-weight heparin. [in French] Ann Fr Anesth Reanim. 2000;19:751–754
  92. Myers B, Westby J, Strong J. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul Fibrinolysis. 2003;14:485–487
  93. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother. 2002;36:489–503
  94. Markwardt F, Fink G, Kaiser B, Klocking HP, Nowak G, Richter M, et al. Pharmacological survey of recombinant hirudin. Pharmazie. 1988;43:202–207
  95. Lindhoff-Last E, Willeke A, Thalhammer C, Nowak G, Bauersachs R. Hirudin treatment in a breastfeeding woman. Lancet. 2000;355:467–468
  96. Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica. 2003;88:147–148
  97. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost. 2002;87:831–835
  98. Rowan JA, McCowan LM, Raudkivi PJ, North RA. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. 2001;185:633–637
  99. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322:329–333
  100. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003;101:1319–1332
  101. Bailey DN, Weibert RT, Naylor AJ, Shaw RF. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. J Anal Toxicol. 1982;6:64–68
  102. Findlay JW, DeAngelis RL, Kearney MF, Welch RM, Findlay JM. Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther. 1981;29:625–633
  103. Kierkegaard A. Side and site of deep vein thrombosis in women using oral contraceptives. Acta Obstet Gynecol Scand. 1985;64:399–402
  104. Kierkegaard A. Deep vein thrombosis and the oestrogen content in oral contraceptives: an epidemiological analysis. Contraception. 1985;31:29–41
  105. Cockett FB, Thomas ML. The iliac compression syndrome. Br J Surg. 1965;52:816–821
  106. Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost. 1992;67:519–520
  107. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259–262
  108. Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood. 2002;100:3470–3478
  109. Schafer AI, Levine MN, Konkle BA, Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology (Am Soc Hematol Educ Program). 2003;X:520–539
  110. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191:1024–1029
  111. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181:1113–1117
  112. Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul Fibrinolysis. 1998;9:343–350
  113. Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol. 1995;173:1240–1245
  114. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG. 2003;110:139–144
  115. Sephton V, Farquharson RG, Topping J, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol. 2003;101:1307–1311
  116. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol. 2004;190:495–501
  117. Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv. 1995;50:534–541
  118. Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res. 2001;101:141–154
  119. Baker WH, Mahler DK, Foldes MS, et al. Pneumatic compression devices for prophylaxis of deep venous thrombosis (DVT). Am Surg. 1986;52:371–373

 Please see the Conflict of Interest section at the end of this article.

PII: S0002-9343(07)00741-3

doi: 10.1016/j.amjmed.2007.08.011

The American Journal of Medicine
Volume 120, Issue 10, Supplement 2 , Pages S26-S34 , October 2007

Article Tools